Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Schering-Plough |
---|---|
Information provided by: | Schering-Plough |
ClinicalTrials.gov Identifier: | NCT00605033 |
Post-marketing commitment to the European Medicines Agency to conduct a prospective, controlled study of the transfer from Subutex to Suboxone.
Condition | Intervention | Phase |
---|---|---|
Opiate Dependence Drug Dependence |
Drug: Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484 Drug: Subutex, Buprenorphine Hydrochloride, SCH 28444 |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Active Control, Parallel Assignment |
Official Title: | A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects |
Estimated Enrollment: | 240 |
Study Start Date: | March 2008 |
Study Completion Date: | May 2009 |
Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Suboxone Active ( plus Subutex Placebo): Active Comparator
None
|
Drug: Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484
Suboxone sublingual tablet 4-24 mg, daily for 28 days
|
Subutex Active (plus Suboxone Placebo): Active Comparator
None
|
Drug: Subutex, Buprenorphine Hydrochloride, SCH 28444
Subutex sublingual tablet 4-24 mg, daily for 28 days
|
Ages Eligible for Study: | 15 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Schering-Plough ( Head, Clinical Trials Registry & Results Disclosure Group ) |
Study ID Numbers: | P04843, SWITCH |
Study First Received: | January 17, 2008 |
Last Updated: | June 23, 2009 |
ClinicalTrials.gov Identifier: | NCT00605033 History of Changes |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Buprenorphine Mental Disorders Narcotic Antagonists Substance-Related Disorders Central Nervous System Depressants Disorders of Environmental Origin |
Narcotics Peripheral Nervous System Agents Analgesics Opioid-Related Disorders Analgesics, Opioid Naloxone |
Narcotic Antagonists Physiological Effects of Drugs Central Nervous System Depressants Disorders of Environmental Origin Narcotics Opioid-Related Disorders Pharmacologic Actions Buprenorphine |
Mental Disorders Sensory System Agents Therapeutic Uses Substance-Related Disorders Analgesics Peripheral Nervous System Agents Central Nervous System Agents Analgesics, Opioid |